Impact of the Therapeutic Education on the Quality of Life of the Child Suffering of Food Allergy IgE-mediated

NCT ID: NCT02106169

Last Updated: 2019-04-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-05

Study Completion Date

2016-10-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether therapeutic education can improve the quality of life of the child from 8 to 12 years old suffering of food allergy.

This study also show us if therapeutic education has an effect on the quality of life of child's family.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Food allergy affects 5 - 6% of children. The major risk is anaphylaxis by ingestion of the forbidden allergen. The child and his family have to learn to deal with this risk. Therapeutic education can help the children to take care of their allergy.

Food allergy limits the child socialisation, leads to anxiety/fear, and impairs health-related quality of life. In the day of today, there is no cure treatment. Also, improve the quality of life is one of the goals of the food allergy management.

The impact of therapeutic education on quality of life has never been studied. We intend to study the impact of therapeutic education on the quality of life of children from 8 to 12 years old with IgE mediated food allergy.

Our hypothesis is the quality of life can be improved by therapeutic education.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgE Mediated Food Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Therapeutic education group

At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.

The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours).

Group Type EXPERIMENTAL

Therapeutic education group

Intervention Type BEHAVIORAL

Control group

At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Therapeutic education group

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* IgE mediated food allergy
* Child from 8 to 12 years old (included)
* Family who can have an internet access
* Children which parents have received study's information
* Child who can have a medical examination before inclusion (art. L.1121-11 du CSP).
* Patients who have a medical insurance.

Exclusion Criteria

* Non IgE mediated food allergy
* Child with chronic disease, except asthma and atopic dermatitis
* Patients who already had a therapeutic education for food allergy
* Patient already included in another study
Minimum Eligible Age

8 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

French Society of Allergology

UNKNOWN

Sponsor Role collaborator

Stallergenes laboratories

UNKNOWN

Sponsor Role collaborator

Picot-Lactalis laboratory

UNKNOWN

Sponsor Role collaborator

ALK Industries

UNKNOWN

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chantal KARILA, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Necker hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Necker hospital

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-A01104-41

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Immunotherapy in Young Children With Food Allergy
NCT05738798 ENROLLING_BY_INVITATION NA
Food Oral Immunotherapy for Peanut Allergy
NCT04222491 ENROLLING_BY_INVITATION PHASE2